Mirus Bio Corporation

Mirus Bio Corporation

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

Contact Details

Office Address

Mirus Bio Corporation
545 Science Dr., Suite A
Madison, WI, USA 53711
Phone: (608) 441-2852
Fax: (608) 441-2849

Executives

President, CEO, VP Finance and Administration

Scott Rose

Business Reviews for Mirus Bio Corporation

Related Companies